Interferon alpha signalling and its relevance for the upregulatory effect of transporter proteins associated with antigen processing (TAP) in patients with malignant melanoma

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Heise, Ruth ^a   Amann, Philipp M ^a   Ensslen, Silke ^a   Marquardt, Yvonne ^a   Czaja, Katharina ^a   Joussen, Sylvia ^a   Beer, Daniel ^a   Abele, Rupert ^b   Plewnia, Gabriele ^b   Tampé, Robert ^b   Merk, Hans F ^a   Hermanns, Heike M ^c   Baron, Jens M ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; STAT1 PROTEIN; STAT3 PROTEIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TUMOR MARKER; ABC TRANSPORTER; ALPHA INTERFERON; STAT1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; TAP1 PROTEIN, HUMAN;

A375 CELL LINE; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MELANOMA; MELANOMA CELL LINE; MELANOMA METASTASIS; MIDDLE AGED; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; THP1 CELL LINE; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; ANIMAL; ANTIGEN PRESENTATION; C57BL MOUSE; CANCER TRANSPLANTATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MONONUCLEAR CELL; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; SKIN NEOPLASMS;

ADULT; AGED; ANIMALS; ANTIGEN PEPTIDE TRANSPORTER-1; ANTIGEN PRESENTATION; ATP-BINDING CASSETTE TRANSPORTERS; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; JANUS KINASES; LEUKOCYTES, MONONUCLEAR; MALE; MELANOMA; MICE, INBRED C57BL; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 84954148638     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0146325     Document Type: Article

References (54)

1. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355(1):51-65. PMID: 16822996
2. Baron JM, Heise R, Merk HF, Abuzahra F. Current and future directions in the treatment of metastatic malignant melanoma. Curr Med Chem Anticancer Agents. 2003;3(6):393-8. PMID: 14529447
3. Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005;366(9492):1189-96. PMID: 16198768
4. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372(9633):117-26. doi: 10.1016/S0140-6736 (08) 61033-8 PMID: 18620949
5. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18(12):2444-58. PMID: 10856105
6. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10(5):1670-7. PMID: 15014018
7. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7-17. PMID: 8558223
8. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010;102(7):493-501. doi: 10. 1093/jnci/djq009 PMID: 20179267
9. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522-30. doi: 10.1016/S1470-2045 (15) 70122-1 PMID: 25840693
10. Darnell JE Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415-21. PMID: 8197455
11. Van Boxel-Dezaire AH, Rani MR, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity. 2006;25(3):361-72. PMID: 16979568
12. Lesinski GB, Valentino D, Hade EM, Jones S, Magro C, Chaudhury AR, et al. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. Cancer Immunol Immunother. 2005;54(9):815-25. PMID: 15668815
13. Caraglia M, Marra M, Pelaia G, Maselli R, Caputi M, Marsico SA, et al. Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol. 2005;202(2):323-35. PMID: 15389589
14. Kalvakolanu DV. Alternate interferon signaling pathways. Pharmacol Ther. 2003;100(1):1-29. PMID: 14550502
15. Zhao LJ, Hua X, He SF, Ren H, Qi ZT. Interferon alpha regulates MAPK and STAT1 pathways in human hepatoma cells. Virol J. 2011;8:157. doi: 10.1186/1743-422X-8-157 PMID: 21466707
16. Uddin S, Majchrzak B, Woodson J, Arunkumar P, Alsayed Y, Pine R, et al. Activation of the p38 mitogenactivated protein kinase by type I interferons. J Biol Chem. 1999;274(42):30127-31. PMID: 10514501
17. Kaur S, Uddin S, Platanias LC. The PI3' kinase pathway in interferon signaling. J Interferon Cytokine Res. 2005;25(12):780-7. PMID: 16375606
18. Oancea G, O'Mara ML, Bennett WF, Tieleman DP, Abele R, Tampe R. Structural arrangement of the transmission interface in the antigen ABC transport complex TAP. Proc Natl Acad Sci U S A. 2009;106(14):5551-6. doi: 10.1073/pnas.0811260106 PMID: 19297616
19. Abele R, Tampe R. The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. Physiology (Bethesda). 2004;19:216-24.
20. Herget M, Baldauf C, Scholz C, Parcej D, Wiesmuller KH, Tampe R, et al. Conformation of peptides bound to the transporter associated with antigen processing (TAP). Proc Natl Acad Sci U S A. 2011;108(4):1349-54. doi: 10.1073/pnas.1012355108 PMID: 21205905
21. Arina A, Tirapu I, Alfaro C, Rodriguez-Calvillo M, Mazzolini G, Inoges S, et al. Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. exploiting cross-priming. Exp Hematol. 2002;30(12):1355-64. PMID: 12482496
22. Enk A. [New aspects of immunotherapy of malignant melanoma]. Praxis (Bern 1994). 2001;90(10):403-6.
23. Johnsen AK, Templeton DJ, Sy M, Harding CV. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol. 1999;163(8):4224-31. PMID: 10510359
24. Lankat-Buttgereit B, Tampe R. The transporter associated with antigen processing: function and implications in human diseases. Physiol Rev. 2002;82(1):187-204. PMID: 11773612
25. Abele R, Tampe R. Modulation of the antigen transport machinery TAP by friends and enemies. FEBS Lett. 2006;580(4):1156-63. PMID: 16359665
26. Lens M. Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease. Dermatol Ther. 2006;19(1):9-18. PMID: 16405565
27. Halama N, Zoernig I, Jaeger D. Advanced malignant melanoma: immunologic and multimodal therapeutic strategies. J Oncol. 2010;2010:689893. doi: 10.1155/2010/689893 PMID: 20224761
28. Abuzahra F, Heise R, Joussen S, Dreuw A, Merk H, Zwadlo-Klarwasser G, et al. Adjuvant interferon alfa treatment for patients with malignant melanoma stimulates transporter proteins associated with antigen processing and proteasome activator 28. Lancet Oncol. 2004;5(4):250. PMID: 15050957
29. Baron JM, Abuzahra F. Evidence-based staging system for malignant melanoma: is new necessarily better? Lancet. 2004;364(9432):395-6. PMID: 15288720
30. Tao J, Li Y, Liu YQ, Li L, Liu J, Shen X, et al. Expression of transporters associated with antigen processing and human leucocyte antigen class I in malignant melanoma and its association with prognostic factors. Br J Dermatol. 2008;158(1):88-94. PMID: 17999701
31. Weiergraber O, Hemmann U, Kuster A, Muller-Newen G, Schneider J, Rose-John S, et al. Soluble human interleukin-6 receptor. Expression in insect cells, purification and characterization. Eur J Biochem. 1995;234(2):661-9. PMID: 8536717
32. Meyer TH, Van Endert PM, Uebel S, Ehring B, Tampe R. Functional expression and purification of the ABC transporter complex associated with antigen processing (TAP) in insect cells. FEBS Lett. 1994;351(3):443-7. PMID: 8082812
33. Van Endert PM, Tampe R, Meyer TH, Tisch R, Bach JF, McDevitt HO. A sequential model for peptide binding and transport by the transporters associated with antigen processing. Immunity. 1994;1(6):491-500. PMID: 7895159
34. Skazik C, Heise R, Bostanci O, Paul N, Denecke B, Joussen S, et al. Differential expression of influx and efflux transport proteins in human antigen presenting cells. Exp Dermatol. 2008;17(9):739-47. doi: 10.1111/j.1600-0625.2008.00745.x PMID: 18557925
35. Hermanns HM, Radtke S, Schaper F, Heinrich PC, Behrmann I. Non-redundant signal transduction of interleukin-6-type cytokines. The adapter protein Shc is specifically recruited to rhe oncostatin M receptor. J Biol Chem. 2000;275(52):40742-8. PMID: 11016927
36. Riese A, Eilert Y, Meyer Y, Arin M, Baron JM, Eming S, et al. Epidermal expression of neuropilin 1 protects murine keratinocytes from UVB-induced apoptosis. PLoS One. 2012;7(12):e50944. doi: 10.1371/journal.pone.0050944 PMID: 23251405
37. Sebastian K, Detro-Dassen S, Rinis N, Fahrenkamp D, Muller-Newen G, Merk HF, et al. Characterization of SLCO5A1/OATP5A1, a solute carrier transport protein with non-classical function. PLoS One. 2014;8(12):e83257.
38. Herget M, Oancea G, Schrodt S, Karas M, Tampe R, Abele R. Mechanism of substrate sensing and signal transmission within an ABC transporter: use of a Trojan horse strategy. J Biol Chem. 2007;282(6):3871-80. PMID: 17164240
39. Wald M, Olejar T, Sebkova V, Zadinova M, Boubelik M, Pouckova P. Mixture of trypsin, chymotrypsin and papain reduces formation of metastases and extends survival time of C57Bl6 mice with syngeneic melanoma B16. Cancer Chemother Pharmacol. 2001;47 Suppl: S16-22. PMID: 11561867
40. Dissemond J, Gotte P, Mors J, Lindeke A, Goos M, Ferrone S, et al. Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression. Melanoma Res. 2003;13(3):253-8. PMID: 12777979
41. Kamarashev J, Ferrone S, Seifert B, Boni R, Nestle FO, Burg G, et al. TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. International journal of cancer Journal international du cancer. 2001;95(1):23-8. PMID: 11241306
42. Cresswell AC, Sisley K, Laws D, Parsons MA, Rennie IG, Murray AK. Reduced expression of TAP-1 and TAP-2 in posterior uveal melanoma is associated with progression to metastatic disease. Melanoma Res. 2001;11(3):275-81. PMID: 11468516
43. Maeurer MJ, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C, et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest. 1996;98(7):1633-41. PMID: 8833913
44. Fleischmann CM, Stanton GJ, Fleischmann WR, Jr. Enhanced in vivo sensitivity to interferon with in vitro resistant B16 tumor cells in mice. Cancer Immunol Immunother. 1994;39(3):148-54. PMID: 7923244
45. Lou Y, Seipp RP, Cai B, Chen SS, Vitalis TZ, Choi KB, et al. Tumour immunity and T cell memory are induced by low dose inoculation with a non-replicating adenovirus encoding TAP1. Vaccine. 2007;25(12):2331-9. PMID: 17229499
46. Zhang QJ, Seipp RP, Chen SS, Vitalis TZ, Li XL, Choi KB, et al. TAP expression reduces IL-10 expressing tumor infiltrating lymphocytes and restores immunosurveillance against melanoma. International journal of cancer Journal international du cancer. 2007;120(9):1935-41. PMID: 17278102
47. Rouyez MC, Lestingi M, Charon M, Fichelson S, Buzyn A, Dusanter-Fourt I. IFN regulatory factor-2 cooperates with STAT1 to regulate transporter associated with antigen processing-1 promoter activity. J Immunol. 2005;174(7):3948-58. PMID: 15778351
48. Wang W, Edington HD, Rao UN, Jukic DM, Land SR, Ferrone S, et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res. 2007;13(5):1523-31. PMID: 17332298
49. Wang W, Edington HD, Jukic DM, Rao UN, Land SR, Kirkwood JM. Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma. Cancer Immunol Immunother. 2008;57(9):1315-21. doi: 10.1007/s00262-008-0466-9 PMID: 18386001
50. Kirkwood JM, Farkas DL, Chakraborty A, Dyer KF, Tweardy DJ, Abernethy JL, et al. Systemic interferonalpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med. 1999;5(1):11-20. PMID: 10072444
51. Humpolikova-Adamkova L, Kovarik J, Dusek L, Lauerova L, Boudny V, Fait V, et al. Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein. Eur J Cancer. 2009;45(7):1315-23. doi: 10.1016/j.ejca.2009.01.009 PMID: 19232485
52. Ito N, Eto M, Nakamura E, Takahashi A, Tsukamoto T, Toma H, et al. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol. 2007;25(19):2785-91. PMID: 17602083
53. Kreil S, Waghorn K, Ernst T, Chase A, White H, Hehlmann R, et al. A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon alpha. Haematologica. 2010;95(1):148-52. doi: 10.3324/haematol.2009.011510 PMID: 20065083
54. Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther. 2006;5(4):787-96. PMID: 16648548